Mucormycosis represents the second most frequent invasive mold infection after invasive aspergillosis and its incidence tends to increase around the world [1]. The disease not only affects patients with severe immune defects (e.g. hematologic cancer patients, transplant recipients), but also apparently immunocompetent individuals, such as those with uncontrolled diabetes, sequela of tuberculosis, chronic kidney disease or following severe trauma [1,2]. For these reasons, the burden of mucormycosis is particularly high in low- and middle-income countries with limited access to healthcare structures.
